)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
LeonaBio
LeonaBio (LONA) investor relations material
LeonaBio 12th Annual Cantor Fitzgerald Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.12th Annual Cantor Fitzgerald Global Healthcare Conference summary11 Sep, 2026
Company overview and strategic focus
Recently established, focused on developing lasofoxifene, a unique SERM for metastatic breast cancer.
Raised $246 million and is led by experienced management and investors.
Emphasizes collaboration and aims to become the partner of choice in second-line metastatic breast cancer.
Lasofoxifene development and differentiation
Lasofoxifene is a potent SERM, showing superior activity against ESR1-mutated breast cancer compared to SERDs.
Demonstrates high affinity for mutated estrogen receptors, inactivating them without degrading healthy receptors.
Offers quality-of-life benefits by avoiding antagonism of estrogen receptors in non-breast tissues.
Clinical trial landscape and ELAINE program
ELAINE-1 and ELAINE-2 trials showed promising efficacy and safety, with no significant thrombotic events.
ELAINE-3 is a 600-patient, fully enriched ESR1 mutation trial comparing lasofoxifene-abemaciclib to fulvestrant-abemaciclib.
The trial is powered to detect a clinically meaningful PFS difference, aiming for double-digit months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from LeonaBio
- Net loss rose to $52.0M as cash fell to $51.1M, with urgent need for additional funding.LONA
Q2 2026 - All proposals passed, directors reelected, and no shareholder questions were raised.LONAAGM 2026
- Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.LONAProxy filing
- Proxy covers director elections, auditor ratification, compensation, and ESG oversight.LONAProxy filing
- Q1 2026 net loss rose to $32.9M as R&D spending increased; cash covers 12 months, more funding needed.LONAQ1 2026
- Lasofoxifene plus abemaciclib shows strong promise for ESR1-mutated metastatic breast cancer.LONAStatus update
- Registering 5.5M shares for resale; proceeds from warrant exercise support drug pipeline.LONARegistration filing
- 58.5M shares registered for resale; warrant exercises could yield over $146M for clinical programs.LONARegistration filing
- Secured lasofoxifene license, raised $90M, and advanced clinical pipeline amid higher R&D spend.LONAQ4 2025
Next LeonaBio earnings date
Q3 202613 Nov, 2026
LeonaBio
Next LeonaBio earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Athira Pharma Inc., also known as Athira Pharma, is a late clinical-stage biopharmaceutical company focused on developing small molecules aimed at restoring neuronal health and slowing neurodegeneration. The company's leading product candidate, ATH-1017 (Fosgonimeton), is designed to enhance the activity of the hepatocyte growth factor (HGF) and its receptor, MET. The company is headquartered in Bothell, Washington, and its shares are listed on the NASDAQ.